Background Patients undergoing dialysis have a substantially increased risk of cardiovascular
mortality and morbidity. Although several trials have shown the cardiovascular benefits of …

… Dr de Zeeuw reports receiving funds to his institution from consultant agreements with
Astra Zeneca, Amgen, Abbott, MSD, BMS, Novartis, VITAE, Takeda, Hemocuem, J&J, REATA, …

… We examined whether albuminuria is associated with the de novo development of an
impaired renal function. GFR was 90.3 (SD 16.3) mL/min/1.73m 2 at baseline, and 11.6% of the …

Background Diabetic nephropathy is the leading cause of end-stage renal disease. Interruption
of the renin–angiotensin system slows the progression of renal disease in patients with …

Background Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia
as well as blood pressure, body weight, and albuminuria in people with diabetes. We …

Background Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few
effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–…

Background Lowering LDL cholesterol with statin regimens reduces the risk of myocardial
infarction, ischaemic stroke, and the need for coronary revascularisation in people without …

… ; Haiyan Wang, MD, China; Christoph Wanner, MD, Germany; David Wheeler, MRCP, United
Kingdom; Andrzej Wieczek, MD, Poland; and Dick de Zeeuw, MD, Ph.D., The Netherlands …

Background Anemia is associated with an increased risk of cardiovascular and renal events
among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa …

Background— For the general population, the clinical relevance of an increased urinary
albumin excretion rate is still debated. Therefore, we examined the relationship between urinary …